^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiKa (camrelizumab)

    i
    Other names: INCSHR1210, SHR-1210, HR-301210, INCSHR-1210, SHR1210, HR301210, HR 301210, INCSHR 1210, SHR 1210
    Company:
    CG Invites, HLB Bio Group, Jiangsu Hengrui Pharma, NPO Petrovax
    Drug class:
    PD1 inhibitor
    Related drugs:
    21h
    NeoCamre-HN: Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, National Medical Research Radiological Centre of the Ministry of Health of Russia
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    carboplatin • paclitaxel • AiRuiKa (camrelizumab)
    2d
    Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=19, Not yet recruiting, Beijing Friendship Hospital
    New P2 trial
    |
    AiRuiKa (camrelizumab) • capecitabine • oxaliplatin
    2d
    A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. (clinicaltrials.gov)
    P2, N=68, Not yet recruiting, The Fourth Affiliated Hospital of Zhejiang University School of Medicine
    New P2 trial
    |
    Avastin (bevacizumab) • AiRuiKa (camrelizumab) • capecitabine
    4d
    Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma. (PubMed, Sci Rep)
    The addition of CIK cell therapy to anti-PD-1 antibody showed signals of potential benefit in refractory ccRCC with a tolerable safety profile. This pilot study suggests the combination approach appears feasible and warrants investigation in larger trials in pretreated ccRCC patients.Registry: ClinicalTrials.gov, TRN: NCT03987698, Registration date: 17 June 2019.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    AiRuiKa (camrelizumab)
    7d
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC (clinicaltrials.gov)
    P2, N=94, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    8d
    ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer. (PubMed, World J Surg Oncol)
    The ERBB2 I655V mutation may be associated with improved treatment response to immunotherapy in gallbladder cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TYK2 (Tyrosine Kinase 2)
    |
    PD-L1 expression • HER-2 overexpression • HER-2 mutation
    |
    Focus V (anlotinib) • AiRuiKa (camrelizumab)
    9d
    Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity. (PubMed, Adv Ther)
    Immunotherapy has expanded therapeutic GTN, transforming refractory disease as a result of its immune responsiveness. Checkpoint inhibition not only achieves high remission rates but also offers fertility preservation and long-term survivorship. The future challenge lies in optimizing combination strategies, refining biomarkers, and ensuring equitable global access to these emerging treatments.
    Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    KDR (Kinase insert domain receptor)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    12d
    Neoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort study (ChiCTR2500114600)
    P=N/A, N=150, Not yet recruiting, Harbin medical university cancer hospital; Harbin medical university cancer hospital
    New trial
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • oxaliplatin • irinotecan • leucovorin calcium
    12d
    Hepatic Arterial Infusion Chemotherapy Combined with Camrelizumab and Lenvatinib for Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study (ChiCTR2500113383)
    P=N/A, N=64, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New trial
    |
    Lenvima (lenvatinib) • AiRuiKa (camrelizumab)
    12d
    Neoadjuvant TACE Combined with Camrelizumab and Apatinib for Centrally Located Hepatocellular Carcinoma(NEO-CENTACT): A Single-Arm, Prospective, Exploratory Study (ChiCTR2500112222)
    P=N/A, N=40, Not yet recruiting, West China Hospital, Sichuan University; Sichuan University West China Hospital
    New trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    12d
    Optimization of immunotherapy strategies for locally advanced and metastatic gastric cancer under the guidance of CTCs and ctDNA (ChiCTR2500113727)
    P=N/A, N=200, Recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • docetaxel • Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    12d
    A prospective study of bipolar androgen followed by novel AR inhibitors combined with PD-1 inhibitors in the treatment of mCRPC (ChiCTR2600116595)
    P3, N=30, Recruiting, Beijing Hospital; Beijing Hospital
    New P3 trial
    |
    AiRuiKa (camrelizumab)